Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer?

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 365-370

  Sun, Jong Mu ^a   Ahn, Myung Ju ^a   Ahn, Jin Seok ^a   Um, Sang Won ^a   Kim, Hojoong ^a   Kim, Hong Kwan ^a   Choi, Young Soo ^a   Han, Joungho ^a   Kim, Jhingook ^a   Kwon, O Jung ^a   Shim, Young Mog ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Chemotherapy; Classification; Large cell neuroendocrine carcinoma; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SMOKING; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84863779805     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.04.009     Document Type: Article

References (35)

1. Cardenal F., Lopez-Cabrerizo M.P., Anton A., Alberola V., Massuti B., Carrato A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999, 17:12-18.
2. Hanna N., Bunn P.A., Langer C., Einhorn L., Guthrie T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24:2038-2043.
3. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
4. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
5. Socinski M.A., Smit E.F., Lorigan P., Konduri K., Reck M., Szczesna A., et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009, 27:4787-4792.
6. Sundstrom S., Bremnes R.M., Kaasa S., Aasebo U., Hatlevoll R., Dahle R., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002, 20:4665-4672.
7. Jones M.H., Virtanen C., Honjoh D., Miyoshi T., Satoh Y., Okumura S., et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004, 363:775-781.
8. Asamura H., Kameya T., Matsuno Y., Noguchi M., Tada H., Ishikawa Y., et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006, 24:70-76.
9. Battafarano R.J., Fernandez F.G., Ritter J., Meyers B.F., Guthrie T.J., Cooper J.D., et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005, 130:166-172.
10. Mazieres J., Daste G., Molinier L., Berjaud J., Dahan M., Delsol M., et al. Large cell neuroendocrine carcinoma of the lung: pathological study and clinical outcome of 18 resected cases. Lung Cancer 2002, 37:287-292.
11. Paci M., Cavazza A., Annessi V., Putrino I., Ferrari G., De Franco S., et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 2004, 77:1163-1167.
12. Peng W.X., Sano T., Oyama T., Kawashima O., Nakajima T. Large cell neuroendocrine carcinoma of the lung: a comparison with large cell carcinoma with neuroendocrine morphology and small cell carcinoma. Lung Cancer 2005, 47:225-233.
13. Takei H., Asamura H., Maeshima A., Suzuki K., Kondo H., Niki T., et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002, 124:285-292.
14. Iyoda A., Hiroshima K., Moriya Y., Takiguchi Y., Sekine Y., Shibuya K., et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 2006, 82:1802-1807.
15. Rossi G., Cavazza A., Marchioni A., Longo L., Migaldi M., Sartori G., et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha. PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005, 23:8774-8785.
16. Saji H., Tsuboi M., Matsubayashi J., Miyajima K., Shimada Y., Imai K., et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs 2010, 21:89-93.
17. Yamazaki S., Sekine I., Matsuno Y., Takei H., Yamamoto N., Kunitoh H., et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 2005, 49:217-223.
18. Varlotto J.M., Medford-Davis L.N., Recht A., Flickinger J.C., Schaefer E., Zander D.S., et al. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas?. J Thorac Oncol 2011, 6:1050-1058.
19. Pelosi G., Masullo M., Leon M.E., Veronesi G., Spaggiari L., Pasini F., et al. CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. Virchows Arch 2004, 445:449-455.
20. Veronesi G., Morandi U., Alloisio M., Terzi A., Cardillo G., Filosso P., et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer 2006, 53:111-115.
21. Smit E.F., Fokkema E., Biesma B., Groen H.J., Snoek W., Postmus P.E. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Brit J Cancer 1998, 77:347-351.
22. Crino L., Mosconi A.M., Scagliotti G., Selvaggi G., Novello S., Rinaldi M., et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1999, 17:2081-2085.
23. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
24. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
25. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
26. Jalal S., Ansari R., Govindan R., Bhatia S., Bruetman D., Fisher W., et al. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol 2009, 4:93-96.
27. Moore A.M., Einhorn L.H., Estes D., Govindan R., Axelson J., Vinson J., et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006, 52:93-97.
28. Socinski M.A., Raju R.N., Neubauer M., Smith D.A., Richards D.A., Savin M., et al. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial. J Thorac Oncol 2008, 3:1308-1316.
29. van der Lee I., Smit E.F., van Putten J.W., Groen H.J., Schlosser N.J., Postmus P.E., et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 2001, 12:557-561.
30. Sun J.M., Han J., Ahn J.S., Park K., Ahn M.J. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 2011, 6:1392-1399.
31. Monica V., Scagliotti G.V., Ceppi P., Righi L., Cambieri A., Lo Iacono M., et al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 2009, 15:7547-7552.
32. Auperin A., Arriagada R., Pignon J.P., Le Pechoux C., Gregor A., Stephens R.J., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999, 341:476-484.
33. Slotman B., Faivre-Finn C., Kramer G., Rankin E., Snee M., Hatton M., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007, 357:664-672.
34. Gore E.M., Bae K., Wong S.J., Sun A., Bonner J.A., Schild S.E., et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 2011, 29:272-278.
35. Arriagada R., Le Chevalier T., Riviere A., Chomy P., Monnet I., Bardet E., et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Ann Oncol 2002, 13:748-754.